Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) AI Stock Analysis

• Market Cap: HK$22.21B
• Dividend Yield: N/A
• Average Volume (3M): 5.91M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: 112.97%
• EPS Growth: 37.70%
• Country: HK
• Employees: 450
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 1,024,730,800
• 10 Day Avg. Volume: 5,228,361
• 30 Day Avg. Volume: 5,906,894
• PEG Ratio: 0.36
• Price to Book (P/B): 31.04
• Price to Sales (P/S): 33.57
• P/FCF Ratio: -25.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$38.50
• Price Target Upside: 78.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: HK$20.00 ▼(-7.15% Downside)

The overall stock score is primarily impacted by financial performance and technical analysis. Despite strong revenue growth, the company faces significant challenges with profitability and cash flow management. Technical indicators suggest bearish momentum, and the valuation is unattractive due to negative earnings. These factors collectively result in a low overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for the company's products and a successful expansion strategy in the medical devices market.

Market Position

As a leader in robotic surgical systems, the company benefits from a strong market position, providing a competitive edge in the growing field of minimally invasive surgery.

Product Portfolio Expansion

Expanding the product portfolio enhances market reach and diversifies revenue streams, supporting long-term growth and resilience against market fluctuations.

Negative Factors

Profitability Challenges

Persistent profitability challenges indicate operational inefficiencies and high costs, which could hinder long-term financial stability if not addressed.

Cash Flow Issues

Negative cash flow raises concerns about the company's ability to fund operations and growth internally, potentially limiting future investment opportunities.

High Leverage

High leverage increases financial risk and can strain cash flow, limiting the company's ability to navigate economic downturns or invest in growth initiatives.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.

How the Company Makes Money

The company generates revenue primarily through the sale of its robotic surgical systems and associated instruments, which are sold to hospitals and surgical centers. Key revenue streams include upfront sales of robotic systems, recurring revenue from the sale of consumable instruments, and maintenance contracts for ongoing support and upgrades. Additionally, MicroPort MedBot engages in partnerships with healthcare institutions for clinical studies and training programs, which further contribute to its revenue. The increasing demand for minimally invasive surgical procedures and the expansion of its product portfolio are significant factors driving its earnings.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai MicroPort MedBot demonstrates impressive revenue growth but faces significant challenges in achieving profitability and managing its cash flow effectively. The high leverage and negative cash flow are potential risks that need to be managed to ensure long-term financial stability.

Income Statement

The company has shown significant revenue growth over the past few years, with Total Revenue increasing from 2.15 million in 2021 to 257.25 million in 2024. However, profitability remains a concern with negative Net Income and high negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's Debt-to-Equity ratio is moderately high, reflecting a high level of leverage which could be risky if not managed properly. The Equity Ratio has been decreasing, indicating a declining proportion of equity financing. Return on Equity is negative due to net losses, suggesting challenges in generating returns for shareholders.

Cash Flow

The company struggles with negative Free Cash Flow and Operating Cash Flow, which raises concerns about its ability to generate cash internally. The lack of positive cash flow from operations could limit growth and investment opportunities unless addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	333.70M	257.25M	104.59M	21.60M	2.15M	0.00
Gross Profit	110.71M	86.22M	14.69M	6.56M	919.00K	0.00
EBITDA	-275.57M	-413.34M	-893.36M	-1.05B	-543.84M	-160.93M
Net Income	-478.60M	-642.41M	-1.01B	-1.14B	-582.92M	-208.87M
Balance Sheet
Total Assets	1.50B	1.28B	1.43B	1.93B	2.79B	1.70B
Cash, Cash Equivalents and Short-Term Investments	815.79M	612.23M	507.71M	747.96M	1.94B	1.50B
Total Debt	668.22M	691.33M	560.42M	219.95M	204.68M	19.24M
Total Liabilities	985.94M	1.02B	926.15M	522.25M	401.73M	262.90M
Stockholders Equity	535.11M	278.20M	519.48M	1.42B	2.39B	1.44B
Cash Flow
Free Cash Flow	-233.38M	-340.21M	-634.30M	-1.09B	-674.47M	-118.05M
Operating Cash Flow	-205.18M	-298.12M	-567.84M	-898.48M	-540.49M	-103.04M
Investing Cash Flow	-32.22M	-47.60M	-58.38M	-267.82M	-396.57M	-15.01M
Financing Cash Flow	833.81M	449.96M	385.68M	-27.95M	1.39B	1.56B

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 21.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Neutral. The current price of 21.54 is below the 20-day moving average (MA) of 21.76, below the 50-day MA of 24.27, and above the 200-day MA of 21.09, indicating a neutral trend. The MACD of -0.94 indicates Negative momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 35.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2252.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.36B	19.87	11.24%	1.27%	25.18%	55.79%
2172	58 Neutral	HK$6.29B	28.42	11.79%	1.49%	-5.18%	-9.69%
1302	57 Neutral	HK$6.78B	88.20	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0853	46 Neutral	HK$20.64B	-15.62	-24.77%	―	-1.04%	60.66%
2160	43 Neutral	HK$2.61B	490.91	0.22%	―	-4.38%	―
2252	38 Underperform	HK$22.21B	-40.84	-117.51%	―	112.97%	37.70%

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events

Shanghai MicroPort MedBot Strengthens Audit Committee Governance

Shanghai MicroPort MedBot (Group) Co., Ltd. has established terms of reference for its Audit Committee to enhance decision-making and oversight processes. The Audit Committee is tasked with supervising internal and external audits, ensuring effective internal controls, and providing accurate financial reporting, thereby strengthening the company’s governance and operational transparency.

Shanghai MicroPort MedBot Enhances Governance with New Nomination Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Nomination Committee under its board of directors to enhance corporate governance and streamline the appointment process for directors and senior management. This move aims to optimize board composition and succession planning, ensuring that the company is well-positioned to address future challenges and opportunities.

Shanghai MicroPort MedBot Enhances Corporate Governance with New Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Remuneration and Appraisal Committee under its board of directors to enhance corporate governance. This committee is responsible for formulating appraisal standards and reviewing remuneration policies for directors, supervisors, and senior management, which is expected to optimize the company’s management system and accountability.

Shanghai MicroPort MedBot Establishes Strategy and Development Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. announced the establishment of a Strategy and Development Committee under its board of directors. This committee is tasked with researching and proposing long-term development strategies and major decisions to strengthen the company’s strategic development, optimize investment decision procedures, and improve decision-making effectiveness. The committee will also review and evaluate the company’s financial, marketing, operational, and business performance, as well as study market trends and their potential effects on the company’s growth.

Shanghai MicroPort MedBot Announces Key Appointments and Governance Changes at 2025 EGM

Shanghai MicroPort MedBot (Group) Co., Ltd. held its 2025 Extraordinary General Meeting (EGM) on November 25, 2025, where several key resolutions were passed. These included the appointment of new directors and amendments to the Articles of Association and Rules of Procedure, reflecting the company’s strategic direction and governance enhancements. The successful passing of these resolutions indicates a strong shareholder support and positions the company for future growth and operational efficiency.

Shanghai MicroPort MedBot Announces EGM for Board Appointments and Governance Amendments

Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an extraordinary general meeting scheduled for November 25, 2025, to discuss several key appointments to its board of directors, including both non-executive and independent non-executive roles. Additionally, the meeting will address proposed amendments to the company’s Articles of Association and the Rules of Procedure for the General Meeting of Shareholders, which could impact the company’s governance and operational procedures.

Shanghai MicroPort MedBot Announces Board Reshuffle

Shanghai MicroPort MedBot (Group) Co., Ltd. announced significant changes in its board of directors, with the resignation of Mr. Sun Hongbin, Ms. Fang Cong, and Dr. Li Minghua, who are stepping down to focus on other business commitments. The company has proposed the appointment of Dr. Chang Zhaohua, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, and Ms. Liang Min as new non-executive directors, pending shareholder approval. These changes are expected to bring new perspectives and expertise to the board, potentially impacting the company’s strategic direction and strengthening its position in the medical device industry.

Shanghai MicroPort MedBot’s Toumai Robot Surpasses 100 Global Orders

Shanghai MicroPort MedBot has announced that its core product, the Toumai Laparoscopic Surgical Robot, has surpassed 100 commercial orders worldwide, marking a significant milestone in its commercialization efforts. The company has achieved installations in nearly 80 units globally, with over 15,000 human clinical surgeries performed using Toumai. This expansion includes installations in major hospital systems across multiple continents, highlighting the company’s growing influence in the global high-end medical market.